RT Journal Article SR Electronic T1 2022-RA-209-ESGO A retrospective study of ovarian cancer among elderly – evaluation and prognosis JF International Journal of Gynecologic Cancer JO Int J Gynecol Cancer FD BMJ Publishing Group Ltd SP A222 OP A223 DO 10.1136/ijgc-2022-ESGO.483 VO 32 IS Suppl 2 A1 Miriam Rivka Brezis A1 Shira Peleg Hasson A1 Eliya Shachar A1 Dan Grisaro A1 Ido Laskov A1 Nadav Michaan A1 Lyri Adar A1 Avigail Harpaz A1 Adi Diner A1 Bar Levy A1 Ido Wolf A1 Tamar Safra YR 2022 UL http://ijgc.bmj.com/content/32/Suppl_2/A222.3.abstract AB Introduction/Background Half of epithelial ovarian cancer (EOC) are diagnosed above age 65. Women over 70 have higher morbidity and mortality. Our real-life retrospective study evaluates elderly with EOC.Methodology Women above 70 were classified as ‘elderly’ (N=233) (71–93), and bellow 70 – ‘control cohort’ (N=755) (24–70). Treatment schedule used (6–8 cycles) were 3-weekly regimen (PC-3W) – carboplatin AUC-6 + Paclitaxel 175 mg/m2 on day 1 of a 21-day cycle, and weekly regimen (PC-1W) – carboplatin AUC-2 + paclitaxel 80 mg/m2 on days 1, 8, and 15 of a 28-day cycleResults When comparing elderly to control median overall survival (mOS) was 41.26 (33.05–63.87) vs. 69.78 (50.07–75.01) months respectively (p<0.0001). No statistical differences were shown when comparing toxicities except for grade 2 anemia – 36.49% vs. 19.67% respectively (p<0.0001) and grade 2 alopecia – 44.81% vs. 60.52% respectively (p<0.0001). The use of PC-1W vs. PC-3W was 44.29% vs 47.14% in the elderly compared to 39.03% vs. 60.3% in the control (p<0.0001). Among the elderly mOS was 57.17 vs. 30.00 months for PC-1W and PC-3W respectively (p = 0.0075). No differences in toxicity were shown, when comparing PC-1W to PC-3W in elderly except for grade 2 alopecia – 26.21% vs. 65.18% respectively (p<0.0001), and grade 2 neuropathy – 20.19% vs. 36.61% respectively (p=0.0119)Abstract 2022-RA-209-ESGO Figure 1 View this table:Abstract 2022-RA-209-ESGO Tabel 1 Abbreviations OS = overall survival, PFS = Progression free survivalConclusion mOS is reduced in elderly, though better than expected, furthermore toxicity is tolerable in elderly. PC-1W was both more abundant and had better mOS in the elderly population. Therefore PC-1W regimen may offer advantages for elderly in terms of tolerance while retaining efficacy.